Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

11141. Percutaneous radiofrequency ablation for primary and secondary lung cancers

lung cancers shows that there are no major safety concerns with this procedure. There is evidence that the treatment can reduce tumour bulk; however, this evidence is limited and is based on heterogeneous indications for treatment. The procedure should therefore be used only with special arrangements for consent, audit and clinical governance. 1.2 Clinicians wishing to undertake percutaneous radiofrequency ablation for primary and secondary lung cancers should take the following actions. - Inform (...) Percutaneous radiofrequency ablation for primary and secondary lung cancers Percutaneous radiofrequency ablation for primary and secondary lung cancers Percutaneous radiofrequency ablation for primary and secondary lung cancers National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health

2006 Health Technology Assessment (HTA) Database.

11142. Management of small cell lung cancer

for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 143. 2006 Authors' objectives This is a systematic review of evidence on issues in managing small cell lung cancer (SCLC). Key questions addressed are: the sequence, timing and dosing characteristics of primary thoracic radiotherapy (TRTx) for limited-stage disease; primary TRTx for extensive-stage disease; effect of prophylactic cranial irradiation (PCI); positron emission tomography (PET) for staging; treatment of mixed (...) histology tumors; surgery; and second- and subsequent-line treatment for relapsed/progressive disease. Authors' conclusions PCI improves survival among those with a complete response to primary therapy. A research agenda is needed to optimize the effectiveness of TRTx and its components. PET for staging may be useful, but its role awaits clarification by rigorous studies. No relevant evidence was available to address management of mixed histology disease or surgery for early limited SCLC. Project page

2006 Health Technology Assessment (HTA) Database.

11143. Testing for HER2 positive breast cancer: a cost-effectiveness analysis

positive status. In the unusual event that a breast cancer patient approaches the hospital with a positive FISH test carried out outside the MUHC, an IHC test needs to be carried out to confirm the course of action. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms /diagnosis; Costs and Cost Analysis; Immunohistochemistry; In Situ Hybridization, Fluorescence Language Published French Country of organisation Canada Province or state Quebec Address for correspondence (...) Testing for HER2 positive breast cancer: a cost-effectiveness analysis Testing for HER2 positive breast cancer: a cost-effectiveness analysis Testing for HER2 positive breast cancer: a cost-effectiveness analysis Dendukuri N, Brophy J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dendukuri N, Brophy J. Testing for HER2 positive breast

2006 Health Technology Assessment (HTA) Database.

11144. Percutaneous laser therapy for fetal tumours

Society. 1.5 Publication of safety and efficacy outcomes will be useful. The Institute may review the procedure on publication of further evidence. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Cystic Adenomatoid Malformation of Lung, Congenital /therapy; Fetal Diseases /therapy; Fetus; Low-Level Light Therapy; Neoplasms /therapy Language Published English Country of organisation England Address for correspondence MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 (...) Percutaneous laser therapy for fetal tumours Percutaneous laser therapy for fetal tumours Percutaneous laser therapy for fetal tumours National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Percutaneous laser therapy for fetal tumours. London: National Institute

2006 Health Technology Assessment (HTA) Database.

11145. Percutaneous cementoplasty for palliative treatment of bony malignancies

Percutaneous cementoplasty for palliative treatment of bony malignancies Percutaneous cementoplasty for palliative treatment of bony malignancies Percutaneous cementoplasty for palliative treatment of bony malignancies National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical (...) Excellence. Percutaneous cementoplasty for palliative treatment of bony malignancies. London: National Institute for Health and Clinical Excellence (NICE). Interventional Procedure Guidance 179. 2006 Authors' objectives This study aims to assess the current evidence on percutaneous cementoplasty for palliative treatment of bony malignancies. Authors' conclusions 1 Guidance 1.1 Current evidence on the safety and efficacy of percutaneous cementoplasty for the palliative treatment of bony malignancies

2006 Health Technology Assessment (HTA) Database.

11146. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer

-refractory metastatic prostate cancer only if their Karnofsky performance-status score is 60% or more. 1.2 It is recommended that treatment with docetaxel should be stopped: - at the completion of planned treatment of up to 10 cycles, or - if severe adverse events occur, or - in the presence of progression of disease as evidenced by clinical or laboratory criteria, or by imaging studies. 1.3 Repeat cycles of treatment with docetaxel are not recommended if the disease recurs after completion (...) Docetaxel for the treatment of hormone-refractory metastatic prostate cancer Docetaxel for the treatment of hormone-refractory metastatic prostate cancer Docetaxel for the treatment of hormone-refractory metastatic prostate cancer National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health

2006 Health Technology Assessment (HTA) Database.

11147. Improving outcomes for people with brain and other CNS tumours: the manual

and Clinical Excellence. Improving outcomes for people with brain and other CNS tumours: the manual. London: National Institute for Health and Clinical Excellence (NICE). Guidance on Cancer Services. 2006 Authors' objectives The aim of this guidance is to point the way to improving outcomes for people with brain and other central nervous system (CNS) tumours. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Brain Neoplasms; Central Nervous System Neoplasms; Practice Guidelines (...) Improving outcomes for people with brain and other CNS tumours: the manual Improving outcomes for people with brain and other CNS tumours: the manual Improving outcomes for people with brain and other CNS tumours: the manual National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health

2006 Health Technology Assessment (HTA) Database.

11148. Sentinel lymph node biopsy in breast cancer

Sentinel lymph node biopsy in breast cancer Sentinel lymph node biopsy in breast cancer Sentinel lymph node biopsy in breast cancer Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Sentinel lymph node biopsy in breast cancer. Canberra: Medical Services Advisory (...) Committee (MSAC). MSAC Application 1065. 2006 Authors' objectives This report aims to determine whether sentinel lymph node biopsy (SLNB) for breast cancer can identify patients for whom axillary clearance (AC) is not indicated (i.e. who are lymph node negative), without increasing axillary recurrence rates or decreasing long-term survival. Authors' conclusions Sentinel node biopsy appears to be safe and effective in identifying sentinel lymph nodes resulting in the reduction of complications due

2006 Health Technology Assessment (HTA) Database.

11149. Cancer care quality measures: symptoms and end-of-life care

Cancer care quality measures: symptoms and end-of-life care Cancer care quality measures: symptoms and end-of-life care Cancer care quality measures: symptoms and end-of-life care Lorenz K, Lynn K, Dy S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Lorenz K, Lynn K, Dy S. Cancer care quality measures: symptoms and end-of-life care (...) . Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 137. 2006 Authors' objectives The aim of this report was to systematically identify quality measures and the evidence for them. to support quality assessment and improvement in the palliative care of patients with cancer in the areas of pain, dyspnea, depression, and advance care planning (ACP), and to identify important gaps in related research. Authors' conclusions A large number of measures

2006 Health Technology Assessment (HTA) Database.

11150. Cancer care quality measures: diagnosis and treatment of colorectal cancer

Cancer care quality measures: diagnosis and treatment of colorectal cancer Cancer care quality measures: diagnosis and treatment of colorectal cancer Cancer care quality measures: diagnosis and treatment of colorectal cancer Patwardhan MB, Samsa GP, McCrory DC, Fisher DA, Mantyh CR, Morse MA, Prosnitz RG, Cline KE, Gray RN Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Patwardhan MB, Samsa GP, McCrory DC, Fisher DA, Mantyh CR, Morse MA, Prosnitz RG, Cline KE, Gray RN. Cancer care quality measures: diagnosis and treatment of colorectal cancer. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 138. 2006 Authors' objectives The aim of this report was to identify measures that are currently available to assess the quality of care provided to patients with colorectal cancer (CRC

2006 Health Technology Assessment (HTA) Database.

11151. Proton beam therapy for prostate cancer

Proton beam therapy for prostate cancer Proton beam therapy for prostate cancer Proton beam therapy for prostate cancer HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Proton beam therapy for prostate cancer. Lansdale: HAYES, Inc.. Directory Publication. 2006 Authors' objectives Proton beam therapy (PBT) is a type of external radiation (...) treatment in which positively charged subatomic particles (protons) are precisely targeted to a specific tissue mass by using a sophisticated stereotaxic planning and delivery system. In comparison with conventional photon irradiation, proton beam radiation may deliver a higher dose to the target tissue, while minimizing exposure to surrounding healthy tissue. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Neutrons; Prostatic Neoplasms

2006 Health Technology Assessment (HTA) Database.

11152. Neutron beam therapy for prostate cancer

Neutron beam therapy for prostate cancer Neutron beam therapy for prostate cancer Neutron beam therapy for prostate cancer HAYES, Inc. Citation HAYES, Inc.. Neutron beam therapy for prostate cancer. Lansdale: HAYES, Inc.. Directory Publication. 2006 Authors' objectives Neutron beam therapy (NBT) is a form of external beam radiotherapy in which accelerated neutral subatomic particles (neutrons) are targeted to a tumor mass, with the goal of eradicating malignant cells. Unlike standard photon (x (...) -ray) radiotherapy (XRT), which is characterized by low linear energy transfer (LET), NBT involves high-LET. Compared with XRT, the high-LET of NBT is associated with greater cell killing per unit dose and, theoretically, is superior in overcoming radioresistance in slowly proliferating tumors such as prostate adenocarcinoma. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Neutrons; Prostatic Neoplasms /radiotherapy; Radiotherapy

2006 Health Technology Assessment (HTA) Database.

11153. Human papillomavirus vaccines for prevention of cervical cancer

' objectives Vaccines targeting high-risk human papillomavirus (HPV) types that have been associated with cervical cancer have recently been developed. The goal of vaccination using these HPV vaccines is to prevent and/or control persistent HPV infection and associated disease, and thus prevent cervical cancer. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Female; Papillomavirus Infections /diagnosis; Tumor Virus Infections /diagnosis; Uterine (...) Cervical Diseases /prevention& Uterine Cervical Neoplasms /prevention& Vaginal Smears; control; control Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32006001574 Date bibliographic record published 08/12/2006 Date abstract record published 12/05/2010

2006 Health Technology Assessment (HTA) Database.

11154. Sutent (sunitinib malate) for gastrointestinal stromal tumour (GIST): horizon scanning technology ultra-orphan note

Sutent (sunitinib malate) for gastrointestinal stromal tumour (GIST): horizon scanning technology ultra-orphan note Sutent (sunitinib malate) for gastrointestinal stromal tumour (GIST): horizon scanning technology ultra-orphan note Sutent (sunitinib malate) for gastrointestinal stromal tumour (GIST): horizon scanning technology ultra-orphan note NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation NHSC. Sutent (sunitinib malate) for gastrointestinal stromal tumour (GIST): horizon scanning technology ultra-orphan note. Birmingham: National Horizon Scanning Centre (NHSC). 2006 Authors' objectives This bulletin looks at sutent (sunitinib malate) for gastrointestinal stromal tumour (GIST). Timeliness warning Available on request from NHSC. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents

2006 Health Technology Assessment (HTA) Database.

11155. Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation

, there should be more data from methodologically sound RCTs. Further research is needed on whether the balance of advantages and disadvantages of laparoscopic surgery varies within subgroups based on the different stages and locations of disease. Research relating to the effect of experience on performance is also required. Project page URL INAHTA brief and checklist Indexing Status Subject indexing assigned by CRD MeSH Colorectal Neoplasms /surgery; Costs and Cost Analysis; Laparoscopy /methods Language (...) Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L

2006 Health Technology Assessment (HTA) Database.

11156. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer

Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Health and Clinical Excellence. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 112. 2006 Authors' objectives The aim of this review is to provide guidance on the use of hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. Authors' conclusions 1 Guidance

2006 Health Technology Assessment (HTA) Database.

11157. [Assessment of the effectiveness of the intraoperative detection of the sentry ganglion in solid tumours]

[Assessment of the effectiveness of the intraoperative detection of the sentry ganglion in solid tumours] Evaluacion de la efectividad de la deteccion intraoperatoria del ganglio centinela en tumores solidos [Assessment of the effectiveness of the intraoperative detection of the sentry ganglion in solid tumours] Evaluacion de la efectividad de la deteccion intraoperatoria del ganglio centinela en tumores solidos [Assessment of the effectiveness of the intraoperative detection of the sentry (...) ganglion in solid tumours] Alvarez S, Rueda JR Citation Alvarez S, Rueda JR. Evaluacion de la efectividad de la deteccion intraoperatoria del ganglio centinela en tumores solidos. [Assessment of the effectiveness of the intraoperative detection of the sentry ganglion in solid tumours] Vitoria-Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-06-01. 2006 Authors' objectives

Assess the effectiveness and reliability of the intraoperative detection of the sentry ganglion

2006 Health Technology Assessment (HTA) Database.

11158. Radiofrequency ablation of liver tumours (update and re-appraisal): a systematic review. Report no. 56

for primary hepatocellular carcinoma or metastatic colorectal liver carcinoma over other ablative treatment techniques. Further studies are also necessary to compare the safety and efficacy of percutaneous, laparoscopic and open approaches to radiofrequency ablation. The relationship of patient safety and efficacy outcomes and tumour size also requires additional research. Lastly, it is recommended that, through the increasing use of health informatics, cancer registries incorporate data items designed (...) systematic review on Radiofrequency Ablation for Liver Tumours, October 2002. This review was initiated in order to assess new studies examining the safety and efficacy of radiofrequency ablation (RFA) for primary hepatocellular carcinoma or metastatic colorectal liver carcinoma, in comparison to other surgical and non-surgical therapeutic techniques, on the basis of a systematic assessment of the literature. The surgical comparative techniques included resection or hepatic artery infusion chemotherapy

2006 Health Technology Assessment (HTA) Database.

11159. NMP22 BladderChek proteomic assay for the detection of bladder cancer - horizon scanning technology note

for the HTA database. Citation NHSC. NMP22 BladderChek proteomic assay for the detection of bladder cancer - horizon scanning technology note. Birmingham: National Horizon Scanning Centre (NHSC). 2006 Authors' objectives To summarise the currently available evidence on NMP22 BladderChek proteomic assay for the detection of bladder cancer. Timeliness warning Available on request from NHSC. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Biomarkers, Tumor /analysis; Diagnostic (...) NMP22 BladderChek proteomic assay for the detection of bladder cancer - horizon scanning technology note NMP22 BladderChek proteomic assay for the detection of bladder cancer - horizon scanning technology note NMP22 BladderChek proteomic assay for the detection of bladder cancer - horizon scanning technology note NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made

2006 Health Technology Assessment (HTA) Database.

11160. [Information required for analysing the impact of the early breast cancer detection programme]

of the short-term results of the Early Breast Cancer Detection Programme in the CAPV.

Authors' conclusions The following recommendations are made: 1. That the Hospital Cancer Registry record tumour extension data according to the TNM classification and correct the variable that specifies whether the cancer has been diagnosed within a screening programme or not, in initial screening, in a subsequent programmed visit or in a subsequent non programmed visit and to incorporate new categories to specify (...) [Information required for analysing the impact of the early breast cancer detection programme] Informacion necesaria para el analisis del impacto del programa de deteccion precoz del cancer de mama [Information required for analysing the impact of the early breast cancer detection programme] Informacion necesaria para el analisis del impacto del programa de deteccion precoz del cancer de mama [Information required for analysing the impact of the early breast cancer detection programme] Rueda J

2006 Health Technology Assessment (HTA) Database.